8-K/AFiled Aug 11, 8:00 PM ET

Bausch & Lomb Corp: Board Chair Change; New Directors Appointed

$BLCO · Bausch & Lomb Corp

Research Summary

AI-generated summary of this SEC filing

Updated

Bausch & Lomb Corp: Board Chair Change; New Directors Appointed

What Happened
Bausch & Lomb Corporation filed an amendment to its Form 8-K reporting board leadership changes effective August 10, 2026. Thomas J. Appio succeeded Brent Saunders as Chairman of the Board (Saunders remains a director). Laurence Paul, M.D., was appointed Lead Independent Director. The amendment follows an Initial 8-K filed August 6, 2026 that reported the resignation of certain directors and the appointment of Thomas J. Appio, Robert J. Chersi, Laurence Paul, M.D., and Barbara J. Trebbi effective August 5, 2026.

Key Details

  • Amendment No. 1 filed August 12, 2026; Initial 8-K filed August 6, 2026 (appointments effective August 5 and committee updates effective August 10, 2026).
  • Committee appointments effective August 10, 2026: Robert J. Chersi added to Audit & Risk and Talent & Compensation; Laurence Paul, M.D. added to Nominating & Corporate Governance and Science & Technology.
  • Committee chairs named: John A. Paulson — Nominating & Corporate Governance; Eduardo Alfonso, M.D. — Science & Technology; Barbara J. Trebbi — Talent & Compensation.
  • Current committee compositions:
    • Audit & Risk: Sarah B. Kavanagh (Chair), Robert J. Chersi, Russel C. Robertson
    • Science & Technology: Eduardo Alfonso, M.D. (Chair), Nathalie Bernier, Laurence Paul, M.D.
    • Nominating & Corporate Governance: John A. Paulson (Chair), Sarah B. Kavanagh, Laurence Paul, M.D.
    • Talent & Compensation: Barbara J. Trebbi (Chair), Robert J. Chersi, Russel C. Robertson

Why It Matters
Board leadership and committee chairs drive corporate governance, oversight of financial reporting, compensation, and R&D strategy—areas investors watch closely for a medical-device company like Bausch & Lomb. These changes clarify who will lead audit, science & technology, nominating/governance, and compensation oversight going forward and may affect how the board supervises strategy and risk. This filing is procedural disclosure of those governance changes rather than an operational or financial announcement.